James Smelser, MD
Nephrology · Huntsville, ALNPI 1881685089
Payments from drug & device makers
Across 464 payments — averaging $369.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$85K
- Vertex$68K
- Nuwellis, Inc.$12K
- Fresenius USA Marketing, Inc.$1K
- AstraZeneca$972
- Otsuka America Pharmaceutical, Inc.$922
- plus $5K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 58 | $84,606 |
| Vertex | 2 | $67,634 |
| Nuwellis, Inc. | 17 | $11,857 |
| Fresenius USA Marketing, Inc. | 49 | $1,016 |
| AstraZeneca(2 entities) | 50 | $972 |
| Otsuka America Pharmaceutical, Inc. | 44 | $922 |
| Vifor Pharma, Inc. | 53 | $883 |
| Amgen(2 entities) | 25 | $597 |
| Calliditas Therapeutics US Inc. | 21 | $536 |
| OPKO Pharmaceuticals, LLC | 63 | $463 |
| Novartis | 13 | $348 |
| Ardelyx, Inc. | 6 | $244 |
| Travere Therapeutics, Inc. | 12 | $237 |
| Mallinckrodt Hospital Products Inc. | 5 | $229 |
| GSK | 12 | $196 |
| Akebia Therapeutics Inc | 3 | $152 |
| Medtronic | 1 | $116 |
| ANI Pharmaceuticals, Inc. | 4 | $115 |
| Boehringer Ingelheim | 4 | $92 |
| Aurinia Pharma U.S., Inc. | 4 | $89 |
| Mallinckrodt Enterprises LLC | 2 | $45 |
| Lilly USA, LLC | 2 | $40 |
| Novo Nordisk | 2 | $36 |
| Nxstage Medical, Inc. | 2 | $35 |
| Baxter Healthcare | 2 | $29 |
| Pfizer | 1 | $28 |
| Lundbeck LLC | 1 | $24 |
| Amicus Therapeutics, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Cycle Pharmaceuticals Inc | 1 | $13 |
How this compares
$171,639 in reported general payments places this provider in the 90th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Huntsville
- David TietjenHuntsville$2.6M
- Michael QuadriniHuntsville$1.3M
- David BainsHuntsville$856K
- Carlo CastilloHuntsville$461K
- Roger CoomerHuntsville$93K
- Todd BroomeHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Dana RizkBirmingham$2.6M
- Eric WallaceBirmingham$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.